TABLE 2.
Outcome and survival of fusariosis patients treated with voriconazole, by site of infection
| Site of infection (no. of patients) | Median (range) duration of voriconazole therapy (days) | No. (%) with clinical response | Median (range) survivala (days) | No. that died (no. that died due to IFI) |
|---|---|---|---|---|
| Brain (4) | 37 (1-75) | 0 (0) | 40 (5-75) | 4 (4) |
| Disseminated (49) | 33 (3-480) | 22 (45) | 84 (4-808) | 30 (16) |
| Lung/sinus (11) | 90 (24-379) | 7 (64) | 329 (29-435) | 5 (1) |
| Otherb (9) | 57 (2-259) | 5 (56) | 202 (19-365) | 4 (1) |
| Total (73) | 57 (1-480) | 34 (47) | 120 (4-808) | 43 (22) |
a
Significant (P = 0.02) for all survival comparisons, based on the log-rank test.
b
Other infection sites were bone (4 patients), gallbladder (1), and superficial (4).